Evaxion Biotech (NASDAQ: EVAX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.330 | -0.250 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Evaxion Biotech (NASDAQ: EVAX) through any online brokerage.
Other companies in Evaxion Biotech’s space includes: Connect Biopharma Hldgs (NASDAQ:CNTB), Celyad Oncology (NASDAQ:CYAD), Applied Genetic (NASDAQ:AGTC), Nymox Pharmaceutical (NASDAQ:NYMX) and OKYO Pharma (NASDAQ:OKYO).
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on Tuesday, March 2, 2021. The analyst firm set a price target for 18.00 expecting EVAX to rise to within 12 months (a possible 800.00% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Evaxion Biotech (NASDAQ: EVAX) is $2 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Evaxion Biotech.
Evaxion Biotech’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Evaxion Biotech.
Evaxion Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.